These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21326923)

  • 1. Bioengineered bugs expressing oligosaccharide receptor mimics: toxin-binding probiotics for treatment and prevention of enteric infections.
    Paton AW; Morona R; Paton JC
    Bioeng Bugs; 2010; 1(3):172-7. PubMed ID: 21326923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designer probiotics for prevention of enteric infections.
    Paton AW; Morona R; Paton JC
    Nat Rev Microbiol; 2006 Mar; 4(3):193-200. PubMed ID: 16462752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea.
    Paton AW; Jennings MP; Morona R; Wang H; Focareta A; Roddam LF; Paton JC
    Gastroenterology; 2005 May; 128(5):1219-28. PubMed ID: 15887106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment and prevention of enteric infections with toxin-binding probiotics.
    Paton AW; Morona R; Paton JC
    Discov Med; 2006 Feb; 6(31):35-9. PubMed ID: 17234126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human milk glycans protect infants against enteric pathogens.
    Newburg DS; Ruiz-Palacios GM; Morrow AL
    Annu Rev Nutr; 2005; 25():37-58. PubMed ID: 16011458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fighting Cholera One-on-One: The Development and Efficacy of Multivalent Cholera-Toxin-Binding Molecules.
    Zuilhof H
    Acc Chem Res; 2016 Feb; 49(2):274-85. PubMed ID: 26760438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-mimic probiotics: potential therapeutics for bacterial toxin-mediated enteric diseases.
    Paton AW; Morona R; Paton JC
    Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):253-5. PubMed ID: 20528111
    [No Abstract]   [Full Text] [Related]  

  • 8. Binding of Vibrio cholera toxin and the heat-labile enterotoxin of Escherichia coli to GM1, derivatives of GM1, and nonlipid oligosaccharide polyvalent ligands.
    Schengrund CL; Ringler NJ
    J Biol Chem; 1989 Aug; 264(22):13233-7. PubMed ID: 2666416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioengineered probiotics, a strategic approach to control enteric infections.
    Amalaradjou MA; Bhunia AK
    Bioengineered; 2013; 4(6):379-87. PubMed ID: 23327986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose.
    Paton AW; Morona R; Paton JC
    Infect Immun; 2001 Mar; 69(3):1967-70. PubMed ID: 11179385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recombinant probiotic for treatment and prevention of cholera.
    Focareta A; Paton JC; Morona R; Cook J; Paton AW
    Gastroenterology; 2006 May; 130(6):1688-95. PubMed ID: 16697733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial glycosyltransferase toxins.
    Jank T; Belyi Y; Aktories K
    Cell Microbiol; 2015 Dec; 17(12):1752-65. PubMed ID: 26445410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of Shiga-like toxin binding to chemically synthesized oligosaccharide sequences.
    Armstrong GD; Fodor E; Vanmaele R
    J Infect Dis; 1991 Dec; 164(6):1160-7. PubMed ID: 1659599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recognition of human milk oligosaccharides by bacterial exotoxins.
    El-Hawiet A; Kitova EN; Klassen JS
    Glycobiology; 2015 Aug; 25(8):845-54. PubMed ID: 25941008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial toxin inhibitors based on multivalent scaffolds.
    Branson TR; Turnbull WB
    Chem Soc Rev; 2013 Jun; 42(11):4613-22. PubMed ID: 23263178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial enteric infections and vaccine development.
    Holmgren J; Svennerholm AM
    Gastroenterol Clin North Am; 1992 Jun; 21(2):283-302. PubMed ID: 1512046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionation and analysis of lipopolysaccharide-derived oligosaccharides by zwitterionic-type hydrophilic interaction liquid chromatography coupled with electrospray ionisation mass spectrometry.
    Man-Kupisinska A; Bobko E; Gozdziewicz TK; Maciejewska A; Jachymek W; Lugowski C; Lukasiewicz J
    Carbohydr Res; 2016 Jun; 427():29-37. PubMed ID: 27085741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands.
    Kitov PI; Sadowska JM; Mulvey G; Armstrong GD; Ling H; Pannu NS; Read RJ; Bundle DR
    Nature; 2000 Feb; 403(6770):669-72. PubMed ID: 10688205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prebiotics and resistance to gastrointestinal infections.
    Gibson GR; McCartney AL; Rastall RA
    Br J Nutr; 2005 Apr; 93 Suppl 1():S31-4. PubMed ID: 15877892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide.
    Jacewicz M; Clausen H; Nudelman E; Donohue-Rolfe A; Keusch GT
    J Exp Med; 1986 Jun; 163(6):1391-404. PubMed ID: 3519828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.